Pharmacoepidemiologist Jobs in USA with Visa Sponsorship
Pharmacoepidemiologist positions are well-positioned for H-1B visa sponsorship due to their specialized nature and advanced degree requirements. Most roles require a PhD in epidemiology, pharmacology, or biostatistics, clearly meeting specialty occupation criteria for visa purposes. For detailed occupation requirements, see the O*NET profile.
Find Pharmacoepidemiologist JobsOverview
Showing 5 of 992+ Pharmacoepidemiologist jobs
See all 992+ Pharmacoepidemiologist Jobs
Sign up for free to unlock all listings, filter by visa type, and get alerts for new Pharmacoepidemiologist roles.
Get Access To All JobsBackground: Multiple openings are available for highly motivated and creative postdoctoral fellows in the bioinformatics and computational biology field, to join the Xu Lab at UT Southwestern Medical Center. We are seeking a motivated bioinformatics postdoctoral fellow with interests in computational analysis of complex biological data. The successful candidate will work with diverse multi-omic datasets, develop and refine analytical pipelines, and help translate biological questions into computationally driven insights. This position offers an excellent opportunity to strengthen in-demand bioinformatics and data science skills, work in a collaborative environment with both computational and experimental researchers, and contribute to impactful publications and discoveries that support future careers in academia, industry, or biotech. Meanwhile, I also recruit new postdoc fellows on large language models (LLMs) directions. Xu lab pioneers the application of artificial intelligence (AI) — particularly foundation models and LLMs — to drive biological and medical discovery, with a focus on interpretable and generalizable AI frameworks that extend foundation models into genomics, epigenomics, and precision medicine. For example, his team developed an AI-based approach to identify cardiovascular disease genes and validated these findings experimentally in a novel mouse model and preclinical studies, leading to publication in Nature in 2020. More recently, his team developed an LLM-based method that enabled the discovery and experimental validation of a new transcriptional biosensor, published in Science in 2026. His lab has also published multiple LLM algorithms in biology and medical applications, including DEEP-Align, DeMoP, MedLLMCoach, OmniHealthFM, and others. Dr. Lin Xu has developed multiple deep learning models and statistical algorithms to identify novel disease genes and therapeutic targets [e.g., Huang et al. Nature (2020), Lu et al. Nature Machine Intelligence (2022), Chai et al. Nature Medicine (2022), Takahiko et al. Science Translational Medicine (2022) (Cover Story), Shi et al. Cancer Cell (2022), Lebek et al. Science (2023), Xu et al. Nature Communications (2023), Zhu et al. Cancer Cell (2023), Zhang et al. Journal of Clinical Investigation (2023), He et al. Nature Communications (2023), Yu et al. Nature Communications (2023), Santos et al. Nature Communications (2023), Li et al. Nature Communications (2023), Wei et al. Cell (2023), Hernandez et al. PNAS (2024), Hu L et al. Mol Cell (2024), Eglenen-Polat et al. Nature Communications (2024), Lin CC et al. Nature Communications (2024), Xu L. et al. Nature Communications (2024), Venkateswaran N. et al. Nature Communications (2024), Chen S. et al. Nature Communications (2025), Liao C, Nature Communications (2025), Yang X. et al. Nature Immunology (2025), Lu ZY. et al. Nature Communications (2025), Zhou Y. et al. Nature Communications (2025), Adachi Y et al. J Clin Invest. (2025), Napolitano F, et al. J Clin Invest. (2025), Bann et al. Circulation (2025), Ding et al. Circulation (2025), Caravia XM, et al. Proc. Natl. Acad. Sci. (2025), Guan P, et al. Proc. Natl. Acad. Sci. (2025), Engreitz JM, et al. Nature (2025), Li H et al., Science (2026)].
Since 2022, his lab’s research has been published in a series of high-impact journals, including Nature, Science, Cell, Nature Medicine, Cancer Cell, eLife, PNAS, Nature Machine Intelligence, Nature Immunology, Nature Metabolism, Nature Communications, Science Translational Medicine, Science Advances, Molecular Cell, Genes & Development, Cell Reports, Journal of Clinical Investigation, Circulation, Circulation Research, and Developmental Cell. Building on these publications in bioinformatics and AI fields, the Xu Lab has received support from multiple funding sources, including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Cancer Prevention and Research Institute of Texas (CPRIT), U.S. Department of Defense (DoD), Hyundai Foundation, Children’s Cancer Fund, Sam Day Foundation, Rally Foundation, and Andrew McDonough B+ Foundation. Therefore, these new openings will be supported on a multi-year basis.
Position Title: Postdoctoral fellow
Position Qualifications:
1) Experience with NGS data analysis and development of customized sequencing-analysis pipelines is strongly preferred.
2) Experience with Linux environments and command-line tools is required.
3) Doctoral degree in bioinformatics, genetics/genomics, statistics, biostatistics, computer science, systems biology, or a related field.
4) Excellent spoken and written English communication skills.
Contact: Candidates should email a CV/resume directly to: Lin Xu, Ph.D. (Lin.Xu@UTSouthwestern.edu)
Application Deadline: Open until filled; applications will be reviewed on a rolling basis.
Background: Multiple openings are available for highly motivated and creative postdoctoral fellows in the bioinformatics and computational biology field, to join the Xu Lab at UT Southwestern Medical Center. We are seeking a motivated bioinformatics postdoctoral fellow with interests in computational analysis of complex biological data. The successful candidate will work with diverse multi-omic datasets, develop and refine analytical pipelines, and help translate biological questions into computationally driven insights. This position offers an excellent opportunity to strengthen in-demand bioinformatics and data science skills, work in a collaborative environment with both computational and experimental researchers, and contribute to impactful publications and discoveries that support future careers in academia, industry, or biotech. Meanwhile, I also recruit new postdoc fellows on large language models (LLMs) directions. Xu lab pioneers the application of artificial intelligence (AI) — particularly foundation models and LLMs — to drive biological and medical discovery, with a focus on interpretable and generalizable AI frameworks that extend foundation models into genomics, epigenomics, and precision medicine. For example, his team developed an AI-based approach to identify cardiovascular disease genes and validated these findings experimentally in a novel mouse model and preclinical studies, leading to publication in Nature in 2020. More recently, his team developed an LLM-based method that enabled the discovery and experimental validation of a new transcriptional biosensor, published in Science in 2026. His lab has also published multiple LLM algorithms in biology and medical applications, including DEEP-Align, DeMoP, MedLLMCoach, OmniHealthFM, and others. Dr. Lin Xu has developed multiple deep learning models and statistical algorithms to identify novel disease genes and therapeutic targets [e.g., Huang et al. Nature (2020), Lu et al. Nature Machine Intelligence (2022), Chai et al. Nature Medicine (2022), Takahiko et al. Science Translational Medicine (2022) (Cover Story), Shi et al. Cancer Cell (2022), Lebek et al. Science (2023), Xu et al. Nature Communications (2023), Zhu et al. Cancer Cell (2023), Zhang et al. Journal of Clinical Investigation (2023), He et al. Nature Communications (2023), Yu et al. Nature Communications (2023), Santos et al. Nature Communications (2023), Li et al. Nature Communications (2023), Wei et al. Cell (2023), Hernandez et al. PNAS (2024), Hu L et al. Mol Cell (2024), Eglenen-Polat et al. Nature Communications (2024), Lin CC et al. Nature Communications (2024), Xu L. et al. Nature Communications (2024), Venkateswaran N. et al. Nature Communications (2024), Chen S. et al. Nature Communications (2025), Liao C, Nature Communications (2025), Yang X. et al. Nature Immunology (2025), Lu ZY. et al. Nature Communications (2025), Zhou Y. et al. Nature Communications (2025), Adachi Y et al. J Clin Invest. (2025), Napolitano F, et al. J Clin Invest. (2025), Bann et al. Circulation (2025), Ding et al. Circulation (2025), Caravia XM, et al. Proc. Natl. Acad. Sci. (2025), Guan P, et al. Proc. Natl. Acad. Sci. (2025), Engreitz JM, et al. Nature (2025), Li H et al., Science (2026)].
Since 2022, his lab’s research has been published in a series of high-impact journals, including Nature, Science, Cell, Nature Medicine, Cancer Cell, eLife, PNAS, Nature Machine Intelligence, Nature Immunology, Nature Metabolism, Nature Communications, Science Translational Medicine, Science Advances, Molecular Cell, Genes & Development, Cell Reports, Journal of Clinical Investigation, Circulation, Circulation Research, and Developmental Cell. Building on these publications in bioinformatics and AI fields, the Xu Lab has received support from multiple funding sources, including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Cancer Prevention and Research Institute of Texas (CPRIT), U.S. Department of Defense (DoD), Hyundai Foundation, Children’s Cancer Fund, Sam Day Foundation, Rally Foundation, and Andrew McDonough B+ Foundation. Therefore, these new openings will be supported on a multi-year basis.
Position Title: Postdoctoral fellow
Position Qualifications:
1) Experience with NGS data analysis and development of customized sequencing-analysis pipelines is strongly preferred.
2) Experience with Linux environments and command-line tools is required.
3) Doctoral degree in bioinformatics, genetics/genomics, statistics, biostatistics, computer science, systems biology, or a related field.
4) Excellent spoken and written English communication skills.
Contact: Candidates should email a CV/resume directly to: Lin Xu, Ph.D. (Lin.Xu@UTSouthwestern.edu)
Application Deadline: Open until filled; applications will be reviewed on a rolling basis.
See all 992+ Pharmacoepidemiologist Jobs
Sign up for free to unlock all listings, filter by visa type, and get alerts for new Pharmacoepidemiologist roles.
Get Access To All JobsTips for Finding Pharmacoepidemiologist Jobs
Target pharmaceutical companies and research institutions
Large pharma companies like Pfizer, Merck, and Johnson & Johnson regularly sponsor H-1B visas for research roles. Academic medical centers also frequently sponsor pharmacoepidemiologists for faculty positions.
Emphasize your PhD and specialized training
Most pharmacoepidemiologist positions require a PhD in epidemiology, biostatistics, or related field. This advanced degree requirement strongly supports H-1B specialty occupation criteria during USCIS review.
Consider contract research organizations (CROs)
Companies like IQVIA, Covance, and PPD frequently hire pharmacoepidemiologists for drug safety studies. Many CROs have established visa sponsorship processes for specialized research talent.
Highlight experience with regulatory submissions
Experience preparing FDA submissions, PBRER reports, or regulatory documents demonstrates specialized knowledge that supports visa applications. Mention specific therapeutic areas and regulatory experience in applications.
Network through professional organizations
Join ISPE (International Society for Pharmacoepidemiology) and attend conferences. Many positions are filled through professional networks before being posted publicly, especially at pharmaceutical companies.
Consider government contractor roles
FDA contractors and organizations like Acumen LLC frequently hire pharmacoepidemiologists for post-market surveillance projects. These roles often offer visa sponsorship and provide valuable regulatory experience.
Frequently Asked Questions
What degree requirements support H-1B approval for pharmacoepidemiologist roles?
Most pharmacoepidemiologist positions require a PhD in epidemiology, pharmacology, biostatistics, or public health. This advanced degree requirement clearly establishes the role as a specialty occupation under H-1B criteria. A master's degree with extensive research experience may qualify for some positions, but PhD is preferred for strongest visa case.
Do pharmaceutical companies regularly sponsor H-1B visas for pharmacoepidemiologists?
Yes, major pharmaceutical companies frequently sponsor H-1B visas for pharmacoepidemiologists due to the specialized nature of drug safety research. Companies like Pfizer, Merck, Bristol Myers Squibb, and Johnson & Johnson have established track records of visa sponsorship for research positions requiring advanced degrees in epidemiology or biostatistics.
Can international PhD students transition directly to pharmacoepidemiologist roles on H-1B?
Yes, PhD graduates in epidemiology, biostatistics, or related fields can transition directly from F-1 to H-1B status for pharmacoepidemiologist positions. The advanced degree and specialized research training provide strong support for specialty occupation requirements. Many pharmaceutical companies recruit directly from university research programs.
What specific experience strengthens H-1B cases for pharmacoepidemiologist positions?
Experience with regulatory submissions, post-market surveillance studies, real-world evidence generation, and database analysis using tools like SAS or R strengthens H-1B applications. Publications in peer-reviewed journals and experience with specific therapeutic areas demonstrate the specialized knowledge required for these research roles.
How to find Pharmacoepidemiologist jobs with visa sponsorship?
To find Pharmacoepidemiologist jobs with visa sponsorship, use Migrate Mate, which specializes in connecting international professionals with sponsoring employers. Focus your search on pharmaceutical companies, biotech firms, regulatory agencies, and contract research organizations that commonly hire epidemiologists. Target H-1B, TN visa, and O-1 visa opportunities, as these are frequently used for specialized healthcare research positions requiring advanced degrees in epidemiology or related fields.
Are there alternative visa options for pharmacoepidemiologists besides H-1B?
O-1 visas may be available for pharmacoepidemiologists with exceptional research records, significant publications, and recognition in drug safety research. Academic positions may support J-1 visa research scholar status. EB-2 NIW green cards are possible for researchers whose work benefits U.S. public health through drug safety improvements.
What is the prevailing wage requirement for sponsored Pharmacoepidemiologist jobs?
U.S. employers sponsoring a visa must pay at least the prevailing wage, which is what workers in the same role, area, and experience level typically earn. The Department of Labor sets this rate to make sure companies aren't hiring foreign workers simply because they'd accept lower pay than a U.S. worker. It varies by job title, location, and experience. You can look up current prevailing wage rates for any occupation and location using the OFLC Wage Search page.